Skip to content

Study · In vitro (cells) · 2026

12 results

[Thymosin β4 inhibits pyroptosis in BV2 microglial cells: a mechanistic study in vitro].

Li YX, Chen CL, Zheng SD, Lai KX, Yang Z, Deng YY, Guo YX

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics1 Jul 2026Cited by 1 (Europe PMC)

PMID42457332 (opens in a new tab)PMCIDPMC13372563 (opens in a new tab)DOI10.7499/j.issn.1008-8830.2512120 (opens in a new tab)PepBankPUB-42457332
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In BV2 microglial cells with LPS and nigericin-induced pyroptosis, Tβ4 alleviated morphological damage.

    In plain wordsIn microglial cells in the lab, Tβ4 reduced visible cell damage from pyroptosis compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseMorphological damage from pyroptosis
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Compared with the pyroptosis group, Tβ4 treatment alleviated morphological damage caused by pyroptosis in BV2 cells.
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  2. 02LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased IL-1β mRNA expression.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered IL-1β messenger RNA compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIL-1β mRNA expression
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  3. 03LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased IFIT1 mRNA expression.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered IFIT1 messenger RNA compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIFIT1 mRNA expression
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  4. 04LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased IFN-β mRNA expression.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered IFN-β messenger RNA compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIFN-β mRNA expression
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  5. 05LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased IL-1β concentration in the cell supernatant.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered IL-1β released into the fluid compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIL-1β concentration in supernatant
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  6. 06LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased NLRP3 protein expression.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered NLRP3 protein compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseNLRP3 protein expression
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  7. 07LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased GSDMD-N protein expression.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered GSDMD-N protein compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseGSDMD-N protein expression
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  8. 08LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased cleaved caspase-1 protein expression.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered cleaved caspase-1 protein compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseCleaved caspase-1 protein expression
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  9. 09LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased phosphorylated STING protein expression.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered phosphorylated STING protein compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Decreasep-STING protein expression
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  10. 10LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased phosphorylated IRF3 protein expression.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered phosphorylated IRF3 protein compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Decreasep-IRF3 protein expression
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  11. 11LabIn vitro (cells)Efficacy outcome

    In BV2 cells with pyroptosis, Tβ4 significantly decreased the cell death rate.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered cell death compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseCell death rate
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).
  12. 12LabIn vitro (cells)Mechanism

    In BV2 cells with pyroptosis, Tβ4 significantly decreased mitochondrial reactive oxygen species levels.

    In plain wordsIn microglial cells in the lab, Tβ4 lowered mitochondrial reactive oxygen species compared with no Tβ4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseMitochondrial ROS levels
    Study

    n: not reported in source

    BV2 microglial cells, LPS plus nigericin pyroptosis model
    Comparator
    Pyroptosis group (LPS plus nigericin, no Tβ4)
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    1 μg/mL · 1 hourAs given in this study.

    Source sentences

    Summary
    Intracellular mRNA expression of IL-1β, IFIT1, and IFN-β; IL-1β concentration in supernatant; protein expression of NLRP3, GSDMD-N, cleaved caspase-1, p-STING, and p-IRF3; cell death rate; and mitochondrial ROS levels were significantly decreased (P0.05).
    1 context sentence
    Summary · context
    BV2 cells were divided into three groups: control group (no treatment), pyroptosis group [stimulated with 1 μg/mL lipopolysaccharide (LPS) for 12 hours, followed by 10 μmol/L nigericin (Nig) treatment for 1 hour], and Tβ4 treatment group (co-incubated with LPS and Nig, then treated with 1 μg/mL Tβ4 for 1 hour).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.